🟢 BioLineRx is trading 11.44% up today amid GLIX1 clinical expansion

BioLineRx is trading at $2.85 (+11.44%), with investors possibly responding to GLIX1’s clinical expansion.

• Reported $0.3 million in second-quarter revenue, a $4.3 million net loss, and $0.3 million in APHEXDA royalties.
• GLIX1’s second cohort is ongoing, with cohort-three dosing planned for September and a planned ovarian-cancer expansion.
• Announced a $3.75 million offering and maintained cash-runway guidance into the first half of 2027.